Respiratory syncytial virus (RSV) is a leading cause of infant/childhood lower respiratory tract infection and hospitalization. Elderly
adults and those with underlying co-morbidities such as chronic obstructive pulmonary disease (COPD) or suffering with
malignancies are also at increased risk of RSV infection related complications. RSV is estimated to be responsible for ~9,000 deaths
per year (US).
An RSV prophylactic vaccine would ideally to reduce the incidence of severe RSV lower respiratory tract infections in "at risk" groups.
Currently a number of approaches are being pursued including live-attenuated viruses and/or recombinant proteins, the most
advanced of which is AstraZeneca/Medimmune's MEDI-534 and MEDI-559.
This MarketVIEW is a comprehensive MS Excel-based model + summary presentation which forecasts the potential
commercial value of new RSV vaccines across global markets to 2030. The model contains value ($ m) and volume (mio doses)
predictions for infants (<1yrs) and various adult target groups. Differing RSV vaccine profiles and related issues such as differential
pricing are also discussed with regard to LO/BASE/HI market uptake scenarios. THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%.
Please review the TERMS and CONDITIONS of purchase.
